In vitro activity of cefditoren against clinical isolates of penicillin-susceptible and penicillin-intermediate strains of Streptococcus pneumoniae isolated in Germany, 1992-1998.
This study investigates the susceptibility to cefditoren of penicillin-susceptible strains of invasive Streptococcus pneumoniae (n = 312) and of penicillin-intermediate strains of S. pneumoniae (n = 30) isolated mainly from patients with respiratory tract infections. The MIC(90)s of penicillin-susceptible and -intermediate isolates were as follows: cefditoren, < or =0.06 and 1 mg/L; penicillin G, < or =0.06 and 0.5 mg/L. Cefditoren showed the highest activity against the penicillin-intermediate strains investigated compared with the other beta-lactam antibiotics and is therefore considered to be a promising agent for the treatment of infections caused by pneumococci with reduced penicillin susceptibility.
Reinert
R R
RR
Institute of Medical Microbiology and National Reference Center for Streptococci, University Hospital (RWTH) Aachen, Pauwelsstrasse 30, D-52057 Aachen, Germany. Reinert@rwth-aachen.de
Al-Lahham
A
A
Lütticken
R
R
D002511:Cephalosporins / Q000494:pharmacology*; D005858:Germany; D006801:Humans; D066298:In Vitro Techniques; D008826:Microbial Sensitivity Tests; D010406:Penicillins / Q000494:pharmacology*; D012141:Respiratory Tract Infections / Q000188:drug therapy / Q000382:microbiology; D013290:Streptococcal Infections / Q000188:drug therapy*; D013296:Streptococcus pneumoniae / Q000187:drug effects* / Q000302:isolation & purification
D002511:Cephalosporins; D010406:Penicillins; C073460:cefditoren